Friday October 20th 2017

[Comment] New evidence for teriflunomide in multiple sclerosis

Multiple sclerosis is an inflammatory demyelinating disorder of the CNS and one of the most common causes of sustained neurological disability in young adults. For 20 years, since immunomodulation was introduced for the treatment of relapse activity, interferon beta and glatiramer acetate have been the mainstay of therapy. These treatments are only partly effective, and their effects on the reduction of disability progression are debated. They are administered subcutaneously or intramuscularly, which might affect acceptance and patient adherence. (Source: Lancet Neurology)

Link¬†–¬†

[Comment] New evidence for teriflunomide in multiple sclerosis

Leave a Comment

More from category

OHSU’s Robertson on coming to grips with his diagnosis
OHSU’s Robertson on coming to grips with his diagnosis

After learning that he has multiple sclerosis, Dr. Joe Robertson was in denial. Then he realized there was no other [Read More]

Concussion in teens increase risk of multiple sclerosis
Concussion in teens increase risk of multiple sclerosis

Researchers from Orebro University in Sweden studied the connection between concussions and multiple sclerosis. They [Read More]

Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk
Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk

A large-scale new study found that concussions in adolescents can increase the risk of later developing multiple [Read More]

Multiple sclerosis: Oligodendrocytes from stemmcells
Multiple sclerosis: Oligodendrocytes from stemmcells

(Heinrich-Heine University Duesseldorf) A scientific collaboration between stem cell researchers of the [Read More]

Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progr
Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progr

/About-the-Society/News/Global-Experts-Publish-Recommendations-for-Overcom [Read More]